MTHFD2 and breast carcinoma: To study whether MTHFD2 knockdown sensitizes breast cancer cells to antineoplastic agents, MDA-MB-231(SA) cells were transfected as previously described, treated with 0.5 or 1 μM methotrexate, cisplatin or paclitaxel for 24 hours followed by measurement of cell viability.